Share

|

eAlerts

|

Register

|

Login
Showcase

>

  • Showcases
  • >
  • UEGW 2020 | Ultraproactive therapeutic drug monitoring does not outperform reactive in IBD
Camera shoot for interview
  • Gastroenterology
  • Conference Coverage & Reporting, Expert Interviews & Discussion

UEGW 2020 | Ultraproactive therapeutic drug monitoring does not outperform reactive in IBD

Peter Bossuyt discusses his pragmatic trial looking at the potential of ultraproactive therapeutic drug monitoring to improve infliximab dosing in patients with inflammatory bowel disease (5:38).

Don’t fall behind!

Get the latest headlines – in your specialties of choice – delivered straight to your inbox.
Register Now

Showcase

Illustration of bladder cancer

JAVELIN Bladder 100 exploratory analyses point to wide use of maintenance avelumab

MEET THE SENIOR TEAM

Lucy Piper

medwireNews Bureau Chief

Related Showcases

|

view all

  • Neurology

Unrestricted oral feedings reported by caregivers and affected persons across severity of…

  • Conference Coverage & Reporting
Clinician using a tablet device
  • Neurology

Pooled analysis demonstrates favorable safety profile for risdiplam

  • Expert Interviews & Discussion
  • Neurology

Feasibility of assisted 6-minute cycle test shown in non-ambulatory SMA patients

  • Conference Coverage & Reporting
  • Neurology

Nusinersen treatment may improve aerobic capacity in adult SMA patients

  • Conference Coverage & Reporting
  • Neurology

Treatment linked to continued stabilization of motor function in adults with SMA

  • Conference Coverage & Reporting
  • Neurology

Study identifies miRNAs upregulated in SMA

  • Conference Coverage & Reporting

Building relationships through trusted content for healthcare professionals

GET STARTED
A global leader in medical content

© 2023 Springer Healthcare Limited.
Part of the Springer Nature Group.

Twitter Icon-social_rss
Social Share
Contact
eAlerts
Register
Login
Terms of Use
Privacy Policy
Cookie Policy